TY - JOUR
T1 - Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy
AU - Harper, Justin
AU - Ribeiro, Susan P.
AU - Chan, Chi Ngai
AU - Aid, Malika
AU - Deleage, Claire
AU - Micci, Luca
AU - Pino, Maria
AU - Cervasi, Barbara
AU - Raghunathan, Gopalan
AU - Rimmer, Eric
AU - Ayanoglu, Gulesi
AU - Wu, Guoxin
AU - Shenvi, Neeta
AU - Barnard, Richard J.O.
AU - Del Prete, Gregory Q.
AU - Busman-Saha, Kathleen
AU - Silvestri, Guido
AU - Kulpa, Deanna A.
AU - Bosinger, Steven E.
AU - Easley, Kirk A.
AU - Howell, Bonnie J.
AU - Gorman, Dan
AU - Hazuda, Daria J.
AU - Estes, Jacob D.
AU - Sekaly, Rafick Pierre
AU - Paiardini, Mirko
N1 - Funding Information:
We thank Stephanie Ehnert, Stacey Weissman, and Chris Souder in the YNPRC Division of Research Resources, and Sherrie Jean, Jen-nifer Wood, and Elizabeth Strobert in YNPRC Veterinary Medicine, for providing animal care and clinical support, respectively. We also acknowledge Thomas Vanderford at the Emory Center for AIDS Research (CFAR) Virology and Molecular Biomarkers Core for performing the quantification of viral loads and SIV-DNA in the IL-10 characterization cohort; Jeffrey Lifson, Rebecca Shoemaker, Kelli Oswald, Randy Fast, and William Bosche at the AIDS and Cancer Virus Program at Frederick National Laboratory for Cancer Research for performing the quantification of viral loads and SIV-DNA/-RNA in the IL-10 neutralization cohort; and Gregory Tharp at the Emory University Nonhuman Primate Genomics Core for collecting RNA-Seq reads. We gratefully acknowledge Romas Geleziunas at Gilead, Katie Kitrinos at ViiV Healthcare, and Guenter Kraus at Johnson & Johnson for providing antiretroviral drugs. The SIVmac239 strain used for infection was purchased from Koen Van Rompay at UC Davis, and the 174xCEM cell line was obtained from Peter Cress-well at the NIH AIDS Reagent Program, NIAID, NIH. The graphical abstract was created using BioRender (biorender.com). Funding for this work was provided via the following awards: NIH/NIAID grant R01AI116379 to M Paiardini; NIH/NIAID grants R21AI122380 and R37AI141258 to RPS; NIH/NHLBI/NIDDK/NINDS/NIDA/ NIAID grant UM1AI164562 to M Paiardini, DAK, and GS; NIH/ OD grants P51OD011132 and U42OD011023 to the Yerkes National Primate Research Center; NIH/NCRR grant R24RR016988 to the Emory Vaccine Center for AIDS Research; NIH/OD grants P51OD011092 and 1S10OD025002-01 to the Oregon National Primate Research Center; and NIH/NCI grants 75N91019D00024 and HHSN261200800001E to Leidos Biomedical Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
Publisher Copyright:
© 2022, Harper et al.
PY - 2022/4/15
Y1 - 2022/4/15
N2 - Interleukin-10 (IL-10) is an immunosuppressive cytokine that signals through STAT3 to regulate T follicular helper (Tfh) cell differentiation and germinal center formation. In SIV-infected macaques, levels of IL-10 in plasma and lymph nodes (LNs) were induced by infection and not normalized with antiretroviral therapy (ART). During chronic infection, plasma IL-10 and transcriptomic signatures of IL-10 signaling were correlated with the cell-associated SIV-DNA content within LN CD4+ memory subsets, including Tfh cells, and predicted the frequency of CD4+ Tfh cells and their cell-associated SIV-DNA content during ART, respectively. In ART-treated rhesus macaques, cells harboring SIV-DNA by DNAscope were preferentially found in the LN B cell follicle in proximity to IL-10. Finally, we demonstrated that the in vivo neutralization of soluble IL-10 in ART-treated, SIV-infected macaques reduced B cell follicle maintenance and, by extension, LN memory CD4+ T cells, including Tfh cells and those expressing PD-1 and CTLA-4. Thus, these data support a role for IL-10 in maintaining a pool of target cells in lymphoid tissue that serve as a niche for viral persistence. Targeting IL-10 signaling to impair CD4+ T cell survival and improve antiviral immune responses may represent a novel approach to limit viral persistence in ART-suppressed people living with HIV.
AB - Interleukin-10 (IL-10) is an immunosuppressive cytokine that signals through STAT3 to regulate T follicular helper (Tfh) cell differentiation and germinal center formation. In SIV-infected macaques, levels of IL-10 in plasma and lymph nodes (LNs) were induced by infection and not normalized with antiretroviral therapy (ART). During chronic infection, plasma IL-10 and transcriptomic signatures of IL-10 signaling were correlated with the cell-associated SIV-DNA content within LN CD4+ memory subsets, including Tfh cells, and predicted the frequency of CD4+ Tfh cells and their cell-associated SIV-DNA content during ART, respectively. In ART-treated rhesus macaques, cells harboring SIV-DNA by DNAscope were preferentially found in the LN B cell follicle in proximity to IL-10. Finally, we demonstrated that the in vivo neutralization of soluble IL-10 in ART-treated, SIV-infected macaques reduced B cell follicle maintenance and, by extension, LN memory CD4+ T cells, including Tfh cells and those expressing PD-1 and CTLA-4. Thus, these data support a role for IL-10 in maintaining a pool of target cells in lymphoid tissue that serve as a niche for viral persistence. Targeting IL-10 signaling to impair CD4+ T cell survival and improve antiviral immune responses may represent a novel approach to limit viral persistence in ART-suppressed people living with HIV.
UR - http://www.scopus.com/inward/record.url?scp=85128489267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128489267&partnerID=8YFLogxK
U2 - 10.1172/JCI155251
DO - 10.1172/JCI155251
M3 - Article
C2 - 35230978
AN - SCOPUS:85128489267
SN - 0021-9738
VL - 132
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 8
M1 - e155251
ER -